Health Canada Consults on Proposed Changes to the List of Recognized Standards for Medical Devices

Key takeaways

• On July 27, 2026, Health Canada opened a consultation on proposed changes to the List of Recognized Standards for Medical Devices.
• The list covers standards relating to device safety, performance, labeling and other areas. Changes may directly affect manufacturers’ compliance pathways and technical documentation requirements.
• Health Canada will also reform the update process by introducing a year-round continuous feedback mechanism, allowing stakeholders to submit comments at any time for incorporation into the annual review.
• The consultation closes on September 25, 2026.
• Stakeholders include medical device manufacturers, regulatory representatives and healthcare professionals.

Full translated core content

Consultation: Proposed changes to the List of Recognized Standards for Medical Devices

Current status: Open. The consultation opened on July 27, 2026, and will close for new comments on September 25, 2026.

Health Canada is seeking feedback on a draft update to the List of Recognized Standards for Medical Devices.

Following this consultation, Health Canada will change the process for updating the List of Recognized Standards by introducing a year-round continuous feedback mechanism. Stakeholders are encouraged to submit comments at any time by email to <standards.committee@hc-sc.gc.ca>.

Feedback received will be compiled on an ongoing basis and incorporated into the annual review of the List of Recognized Standards. This approach supports more timely engagement, improves responsiveness to stakeholder input, and streamlines the process to provide consistent annual updates.

How to participate

• Read the draft document: Review the draft List of Recognized Standards for Medical Devices. When preparing comments, it is recommended that you also refer to the current list in force.
• Send an email: Send your views or comments by email to <standards.committee@hc-sc.gc.ca> to express your perspective.

Who should participate

This consultation is intended for the following groups:

• Medical device manufacturers
• Regulatory representatives
• Healthcare professionals

Key questions for discussion

Health Canada invites feedback on the proposed additions, deletions and updates in the draft list.

Please identify any items that should be added, removed or updated in the list.

Related information

• Food and Drugs Act
• Medical Devices Regulations
• Guidance on the Use of Standards to Support Compliance with the Medical Devices Regulations

Contact

Medical Devices Directorate
Health Products and Food Branch
Health Canada
Address: 11 Holland Ave, Tower A, Address Locator: 3002A, Ottawa ON K1A 0K9
Email: <standards.committee@hc-sc.gc.ca>

Source: Health Canada, Public Health Agency of Canada and/or other departments.
Page details: 2026-07-27.

Source and applicability note

Source organization: Health Canada Medical Devices Announcements.
Original publication date: July 27, 2026.
Source: https://www.canada.ca/en/health-canada/programs/consultation-proposed-changes-list-recognized-standards-medical-devices.html

This article is based on public information from Health Canada Medical Devices Announcements. Specific requirements are subject to the latest official publications of the regulatory authority.

AIMEILI regulatory interpretation and business impact

Health Canada’s consultation on the List of Recognized Standards for Medical Devices, together with the announced process reform, has multiple implications for medical device manufacturers, including Chinese manufacturers active in or planning for the Canadian market.

1. Impact on compliance pathways and technical documentation

The list update directly affects the standards framework that manufacturers must follow to enter the Canadian market. When applying for a Medical Device Licence (MDL) or Medical Device Establishment Licence (MDEL), companies often need to demonstrate conformity with standards listed in the recognized standards list, such as ISO 13485, ISO 14971, and the IEC 60601 series. Changes to the list mean that companies should reassess the conformity of their technical files, performance test reports and risk management documentation.

2. Impact of the year-round feedback and annual review process

The reform moves the update process from periodic updates to a year-round continuous feedback mechanism integrated into annual review. Companies will no longer need to wait for a fixed consultation window to submit suggestions on standards; they may submit comments by email at any time. Companies with Canadian registration plans or registered products should actively use this channel to participate in the standards development process, especially where existing standards are not fully applicable to their product types. In addition, the predictability of the annual review helps companies plan compliance updates in advance and avoid registration delays caused by sudden standards changes.

3. Impact on registration strategy

Companies should review the recognized standards currently applicable to their products and compare them with the additions, deletions or updates in the draft list. For example, if a standard is deleted, companies may need to adopt an alternative standard or provide an equivalence rationale. If a new standard is added, additional testing or documentation may be required. For special categories such as active devices, software-based devices or drug-containing devices, changes in the recognition status of international standards such as IEC 62304 and ISO 14971 may directly affect the completeness of technical files.

4. Impact on quality management systems, labeling and instructions for use

The recognized standards list typically includes standards related to quality management systems (ISO 13485), labeling (ISO 15223-1) and risk management (ISO 14971). Updates to the list may require companies to revise quality manuals, risk management reports, and symbols, warnings and other content in product labels and instructions for use. Chinese manufacturers should establish an internal standards tracking mechanism and convert changes in Canadian recognized standards into internal compliance tasks in a timely manner.

5. Limited consultation window and next steps

The consultation closes on September 25, 2026, leaving a limited window. Companies with Canadian market plans should have their regulatory teams assess the draft as soon as possible and submit comments through their Canadian representatives or directly to Health Canada. Even if they do not submit comments, companies should closely monitor publication of the final list so that registration strategies can be adjusted in time. Companies should also monitor subsequent Health Canada guidance documents to understand transition arrangements between old and new standards.

What documents should companies review first?

Companies should prioritize a review of the product’s intended use, classification basis, ISO 13485 quality system evidence, risk management file, performance verification data, clinical evaluation or clinical evidence, labeling and instructions for use, authorization documents and existing registration certificates.

Common risks

• Unclear classification determination
• Incomplete evidence chain in documentation
• Labeling and instructions for use not localized
• Unclear responsibilities of the authorized representative
• Insufficient post-market maintenance arrangements

FAQ

Can this consultation notice be used directly as a basis for regulatory submission? No. This article is intended for preliminary understanding and project assessment. Formal submissions must be based on the latest requirements of the target regulatory authority, the product classification conclusion and the company’s actual documentation.

What should companies do first after seeing this update? Companies should first conduct a documentation gap assessment to determine whether the update affects the registration pathway, technical file, labeling, quality management system or post-market maintenance.

Content review and scope

This article is intended for preliminary understanding, document preparation and project planning. It does not replace the formal requirements of the target regulatory authority, testing conclusions or legal opinions. Source principles prioritize official regulatory authorities, international organizations, standards bodies and public regulatory materials; industry media and project experience are used only as supporting references.